
Results
2
Artificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI’s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.
2 companies
Nanoform Finland Oyj
Market Cap: €67.9m
Engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States.
NANOFH
€0.78
7D
-8.5%
1Y
-27.8%
Aiforia Technologies Oyj
Market Cap: €64.9m
Together with its subsidiary, Aiforia Inc., provides AI-based image analysis software used in clinical, preclinical, and academic laboratories to pathologists and researchers in Finland, rest of Europe, North America, and internationally.
AIFORIA
€1.87
7D
1.4%
1Y
-42.5%